Table 1. Characteristics of the Ocular Hypertension Treatment Study Training, Validation, and Test Sets.
| Characteristic | No. (%) | P value | ||
|---|---|---|---|---|
| Training set | Validation set | Test set | ||
| Participants, No. | 1147 | 167 | 322 | NA |
| Eyes, No. | 2294 | 334 | 644 | NA |
| Eye visits, No. | 26 313 | 3807 | 7220 | NA |
| Mean age (95% CI), y | 57.2 (56.6 to 57.8) | 57.1 (55.6 to 58.7) | 57.2 (56.1 to 58.2) | >.99 |
| Sex | ||||
| Female | 661 (57.6) | 97 (58.1) | 173 (53.7) | .44 |
| Male | 486 (42.4) | 70 (41.9) | 149 (46.3) | |
| Self-reported race | ||||
| European descent | 871 (75.9) | 120 (71.9) | 238 (73.9) | .43 |
| African descent | 276 (24.1) | 47 (28.1) | 84 (26.1) | |
| Mean baseline visual field MD (95% CI), dB | −0.02 (−0.10 to 0.06) | 0.02 (−0.20 to 0.23) | −0.12 (−0.27 to 0.04) | .50 |
| Baseline photograph-based vertical cup-disc ratio, mean (95% CI) | 0.39 (0.38 to 0.40) | 0.36 (0.33 to 0.40) | 0.39 (0.37 to 0.41) | .28 |
| Did not develop glaucomaa | ||||
| Participants, No. | 955 | 138 | 267 | NA |
| Eyes, No. | 2046 | 298 | 569 | NA |
| Eye visits, No. | 22 796 | 3272 | 6208 | NA |
| Mean visual field MD (95% CI), dB | −0.18 (−0.25 to −0.12) | −0.09 (−0.25 to 0.07) | −0.16 (−0.28 to −0.05) | .53 |
| Developed a POAG end point by visual field or photograph | ||||
| Participants, No. | 192 | 29 | 55 | NA |
| Eyes, No. | 248 | 36 | 75 | NA |
| Eye visits, No. | 3517 | 535 | 1012 | NA |
Abbreviations: MD, mean deviation; NA, not applicable; POAG, primary open-angle glaucoma.
a
The number of eyes includes all eyes for the did not develop glaucoma group plus fellow eyes from a subset of participants in the developed a POAG end point by visual field or photograph group in which one eye developed a POAG end point and the fellow eye did not.